Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.

The androstenedione derivative, exemestane (FCE 24304), is a new orally active irreversible aromatase inhibitor. Fifty-six post-menopausal advanced breast cancer patients entered this study to evaluate the activity of four low exemestane doses in reducing oestrogen levels. The drug's tolerabili...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Zilembo, N., Noberasco, C., Bajetta, E., Martinetti, A., Mariani, L., Orefice, S., Buzzoni, R., Di Bartolomeo, M., Di Leo, A., Laffranchi, A.
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 1995
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2034036/
https://ncbi.nlm.nih.gov/pubmed/7547212
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars